The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

Use of sodium-glucose cotransporter-2 (SGLT2) inhibitors does not appear to raise the risk for fractures in older adults, new research suggests. The data come from a nationwide propensity ...

Patients with T2D and overweight/obesity starting GLP-1 therapy may experience a small but statistically significant increase ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Sodium-glucose transport protein 2 (SGLT2) inhibitor ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide a beneficial choice of treatment for patients with type 2 diabetes (diabetes mellitus/T2DM). It can be used as an alternative for those who ...

The new report compared the benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors with those of other glucose-lowering drugs and found lower rates of heart disease and mortality. A new ...

Please provide your email address to receive an email when new articles are posted on . Last November, at the American College of Rheumatology Convergence 2023, several faculty members presented new ...

A symposium on the new drug class, SGLT2 inhibitors, drew plenty of interest from attendees at the American Diabetes Association meeting in San Francisco. SGLT2 inhibitors have gained notice, both for ...

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...

Adding sodium-glucose cotransporter 2 (SGLT2) inhibitors to standard medical therapy for heart failure with preserved ejection fraction (HFpEF) provides just low-to-intermediate economic value to the ...